MaxCyte, Inc. filings document the regulatory record for a Delaware life sciences tools company with Nasdaq-listed common stock. Its Form 8-K disclosures cover operating results and financial condition, corporate presentations, executive appointments, compensatory arrangements, listing-compliance notices, and cost-structure actions tied to workforce and operating changes.
MaxCyte proxy materials cover annual stockholder meeting matters, including director elections, board-class structure and auditor ratification. Together, the filings describe governance, capital-market status, material events, and formal disclosures related to MaxCyte’s cell-engineering platform business, Strategic Platform License model, and public-company reporting obligations.
MAXCYTE, INC. director Douglas Richard reported awards of restricted stock units and stock options as part of his compensation. He acquired 30,421 RSUs, each representing one future share of common stock, and 49,579 stock options to buy common shares at $1.13 per share.
The annual grants were made under the company’s equity grant policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, assuming he continues to serve. After the RSU grant, his direct common stock holdings total 260,998 shares.
MAXCYTE director Cynthia Collins received new equity awards. On June 17, 2026, she was granted 30,421 restricted stock units, each representing one future share of common stock, and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. Following the grant, she directly holds 111,310 shares of common stock, and the RSUs vest on June 17, 2027 if she continues serving as a director.
MAXCYTE, INC. director Brooke William W received equity awards consisting of common stock and stock options. He was granted 30,421 shares of Common Stock in the form of restricted stock units, each representing a right to one share. These RSUs vest on June 17, 2027, if he continues serving as a non-employee director under the company’s Equity Grant Policy. He was also granted stock options for 49,579 shares of Common Stock at an exercise price of $1.13 per share, expiring on June 16, 2036. Following these awards, he directly holds 181,300 shares of Common Stock.
MAXCYTE, INC. director Patrick J. Balthrop received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with an exercise price of $1.13 per share. The RSU grant was made under the company’s equity grant policy for non-employee directors and is scheduled to vest on June 17, 2027, contingent on his continued service. Following the RSU grant, Balthrop directly holds 80,998 shares of common stock. The stock options, which are also directly held, are exercisable into 49,579 shares of common stock and are scheduled to expire on June 16, 2036.
MAXCYTE, INC. director Yasir B. Al-Wakeel received equity awards as part of his annual non-employee director compensation. He was granted 30,421 shares of Common Stock in the form of restricted stock units, plus stock options for 49,579 shares at an exercise price of $1.13 per share.
The RSUs and option grant were made under the company’s Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, contingent on his continued service. Following the RSU grant, he directly owns 80,998 shares of Common Stock.
MaxCyte, Inc. held its 2026 annual stockholder meeting on June 17, 2026, where investors voted on board composition and the company’s auditor. Stockholders elected three Class II directors: Patrick Balthrop, Cynthia Collins and Stanley Erck, each receiving more votes for than withheld.
Investors also ratified the Audit Committee’s selection of CohnReznick LLP as MaxCyte’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with over 70 million votes cast in favor and minimal opposition or abstentions.
MaxCyte, Inc. has regained compliance with Nasdaq’s minimum bid price rule. The company previously received a notice that its common stock had closed below $1.00 per share for 30 consecutive trading days, putting its Nasdaq Global Select Market listing at risk.
Nasdaq informed MaxCyte that for 10 consecutive business days, from May 27, 2026 to June 9, 2026, the closing bid price of its common stock was at or above $1.00. As a result, MaxCyte now complies with Nasdaq Listing Rule 5450(a)(1), and Nasdaq considers the matter closed.
River Global Investors LLP has disclosed a sizable stake in MaxCyte, Inc., reporting beneficial ownership of 6,529,027 equity shares, equal to about 6.1% of the company. River Global holds sole voting and dispositive power over these shares, meaning it alone decides how they are voted and when they are sold.
The position was built using investment capital from funds managed by River Global. On May 13, 2026, the firm bought 31,000 shares at 1.115 per share and 619,000 shares at 1.1142 per share through brokers in ordinary open-market trades, reinforcing its role as a financial investor rather than a strategic partner.
MaxCyte, Inc. reported first-quarter 2026 results showing lower revenue but a smaller loss as it reduced operating expenses. Revenue was $9.7 million versus $10.4 million a year earlier, driven by weaker core product and license sales, partly offset by higher milestone and royalty revenue.
Core revenue fell to $6.2 million, mainly from lower processing assembly and license revenue, while Strategic Platform License milestones and royalties rose to $3.4 million. Gross margin remained high at 84%. The net loss narrowed to $4.8 million from $10.3 million as research, sales, and administrative costs declined.
MaxCyte ended March 31, 2026 with cash and cash equivalents of $14.6 million, short-term investments of $92.3 million, and long-term investments of $40.8 million. Management states that existing cash, investments, and operating cash flows are expected to fund operations for at least 12 months while it continues investing in its ExPERT cell engineering platform and new products such as the ExPERT DTx.
MaxCyte, Inc. reported first quarter 2026 revenue of $9.7 million, made up of $6.2 million in core revenue and $3.4 million from Strategic Platform License (SPL) program milestones and royalties. Total revenue declined 7% year over year, but the net loss improved to $4.8 million, or $0.04 per share, from $10.3 million a year earlier as operating expenses were reduced.
The company reiterated its full year 2026 revenue guidance of $30–32 million, including core revenue of $25–27 million and SPL program-related revenue of $5 million. MaxCyte’s board authorized a $10 million share repurchase program over one year, while the balance sheet showed total assets of $194.5 million and stockholders’ equity of $167.9 million as of March 31, 2026.